JP2016519107A - Ｔｈ−３０２抗癌療法のための予測および応答のバイオマーカー - Google Patents

Ｔｈ−３０２抗癌療法のための予測および応答のバイオマーカー Download PDF

Info

Publication number
JP2016519107A
JP2016519107A JP2016507634A JP2016507634A JP2016519107A JP 2016519107 A JP2016519107 A JP 2016519107A JP 2016507634 A JP2016507634 A JP 2016507634A JP 2016507634 A JP2016507634 A JP 2016507634A JP 2016519107 A JP2016519107 A JP 2016519107A
Authority
JP
Japan
Prior art keywords
cancer
patient
hypoxia
predetermined value
degree
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016507634A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016519107A5 (OSRAM
Inventor
ハート，チャールズ
イー． セリック，ハロルド
イー． セリック，ハロルド
サン，ジェシカ
Original Assignee
スレッショルド ファーマシューティカルズ，インコーポレイテッド
スレッショルド ファーマシューティカルズ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スレッショルド ファーマシューティカルズ，インコーポレイテッド, スレッショルド ファーマシューティカルズ，インコーポレイテッド filed Critical スレッショルド ファーマシューティカルズ，インコーポレイテッド
Publication of JP2016519107A publication Critical patent/JP2016519107A/ja
Publication of JP2016519107A5 publication Critical patent/JP2016519107A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computed tomography [CT]
    • A61B6/037—Emission tomography

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2016507634A 2013-04-10 2014-04-09 Ｔｈ−３０２抗癌療法のための予測および応答のバイオマーカー Pending JP2016519107A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361810643P 2013-04-10 2013-04-10
US61/810,643 2013-04-10
PCT/US2014/033491 WO2014169035A1 (en) 2013-04-10 2014-04-09 Predictive and response biomarker for th-302 anti-cancer therapy

Publications (2)

Publication Number Publication Date
JP2016519107A true JP2016519107A (ja) 2016-06-30
JP2016519107A5 JP2016519107A5 (OSRAM) 2017-06-01

Family

ID=51689977

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016507634A Pending JP2016519107A (ja) 2013-04-10 2014-04-09 Ｔｈ−３０２抗癌療法のための予測および応答のバイオマーカー

Country Status (4)

Country Link
US (1) US20160296538A1 (OSRAM)
EP (1) EP2983591A4 (OSRAM)
JP (1) JP2016519107A (OSRAM)
WO (1) WO2014169035A1 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015069489A1 (en) 2013-11-06 2015-05-14 Merck Patent Gmbh Predictive biomarker for hypoxia-activated prodrug therapy
US10507210B2 (en) 2014-12-03 2019-12-17 Auckland Uniservices Limited Kinase inhibitor prodrug for the treatment of cancer
US11504075B2 (en) * 2017-12-20 2022-11-22 University Health Network System, methods, and devices for calculating hypoxic fraction and equilibration rate of small molecular weight tracers using dynamic imaging
US20240366640A1 (en) 2021-08-27 2024-11-07 Ascentawits Pharmaceuticals, Ltd. Lyophilized formulation solution and lyophilized formulation, and method and use thereof
WO2023025312A1 (zh) 2021-08-27 2023-03-02 深圳艾欣达伟医药科技有限公司 使用th-302治疗parp抑制剂耐药的患者
WO2023174319A1 (zh) 2022-03-15 2023-09-21 深圳艾欣达伟医药科技有限公司 治疗brca突变癌症患者的方法
CN119384281A (zh) 2022-04-15 2025-01-28 深圳艾欣达伟医药科技有限公司 使用th-302单药或联用parp抑制剂治疗癌症的方法
EP4529926A1 (en) 2022-05-23 2025-04-02 Ascentawits Pharmaceuticals, Ltd. Method for treating cancer by combining alkylating agent prodrug and cell cycle inhibitor
WO2024061346A1 (zh) 2022-09-22 2024-03-28 深圳艾欣达伟医药科技有限公司 乏氧激活的化合物在制备治疗癌症患者的药物中的用途
WO2024179467A1 (zh) * 2023-02-27 2024-09-06 深圳艾欣达伟医药科技有限公司 溶液、冻干制剂、冻干制剂单位包装、注射液及注射液配制方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012006032A2 (en) * 2010-06-28 2012-01-12 Threshold Pharmaceuticals, Inc. Treatment of blood cancer
WO2012009288A2 (en) * 2010-07-12 2012-01-19 Threshold Pharmaceuticals, Inc. Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005508838A (ja) * 2001-03-23 2005-04-07 アフトン コーポレーション 膵癌の組合せ治療
US20070117784A1 (en) * 2005-03-04 2007-05-24 Novacea, Inc. Treatment of hyperproliferative diseases with anthraquinones
EP2350664B1 (en) * 2008-10-21 2021-05-19 ImmunoGenesis, Inc. Treatment of cancer using the hypoxia activated prodrug th-302 in combination with docetaxel or pemetrexed
WO2012008860A2 (en) * 2010-07-16 2012-01-19 Auckland Uniservices Limited Bacterial nitroreductase enzymes and methods relating thereto

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012006032A2 (en) * 2010-06-28 2012-01-12 Threshold Pharmaceuticals, Inc. Treatment of blood cancer
WO2012009288A2 (en) * 2010-07-12 2012-01-19 Threshold Pharmaceuticals, Inc. Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CARLIN, S. & HUMM, J. L.: "PET of hypoxia: current and future perspectives", J. NUCL. MED., vol. 53巻, JPN6017033378, 2012, pages 1171 - 1174, ISSN: 0003633678 *
DUBOIS, L. J. ET AL.: "Preclinical evaluation and validation of [18F]HX4, a promising hypoxia marker for PET imaging", PROC. NATL. ACAD. SCI. USA, vol. 108巻35号, JPN6017033376, 2011, pages 14620 - 14625, ISSN: 0003799618 *

Also Published As

Publication number Publication date
WO2014169035A1 (en) 2014-10-16
EP2983591A1 (en) 2016-02-17
EP2983591A4 (en) 2016-12-28
US20160296538A1 (en) 2016-10-13

Similar Documents

Publication Publication Date Title
JP2016519107A (ja) Ｔｈ−３０２抗癌療法のための予測および応答のバイオマーカー
Haugen et al. Evolving approaches to patients with advanced differentiated thyroid cancer
Menke-van der Houven et al. 89Zr-cetuximab PET imaging in patients with advanced colorectal cancer
Shinchi et al. Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer
Pool et al. mTOR inhibitor RAD001 promotes metastasis in a rat model of pancreatic neuroendocrine cancer
JP2021510380A (ja) 放射線感受性組織における細胞保護薬の選択的堆積およびその使用
CN109640985A (zh) Hdac抑制剂和pd-l1抑制剂的组合疗法
Morris et al. A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer
Kirsch et al. Imaging primary lung cancers in mice to study radiation biology
Schmid et al. Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma
WO2014142220A1 (ja) 抗腫瘍剤
JP2016528217A (ja) 低酸素活性化プロドラッグおよびタキサンの組合せを用いた膵臓癌の治療
Bernards et al. Liposomal irinotecan achieves significant survival and tumor burden control in a triple negative breast cancer model of spontaneous metastasis
Lubner et al. A phase 1, multi-center, open-label, dose-escalation study of 131I-CLR1404 in subjects with relapsed or refractory advanced solid malignancies
Edelman et al. Phase I and pharmacokinetic study of 7-hydroxystaurosporine and carboplatin in advanced solid tumors
RU2017146346A (ru) Комбинированная терапия pac-1
Nishikawa et al. A case treated with nivolumab after small cell lung cancer transformation of mutant EGFR non-small cell lung cancer
Vansteenkiste et al. Everolimus in combination with pemetrexed in patients with advanced non-small cell lung cancer previously treated with chemotherapy: a phase I study using a novel, adaptive Bayesian dose-escalation model
Zheng et al. Longitudinal tumor hypoxia imaging with [18F] FAZA-PET provides early prediction of nanoliposomal irinotecan (nal-IRI) treatment activity
Gutierrez et al. A phase 1 dose-escalation study of the oral selective inhibitor of nuclear export (SINE) KPT-330 (selinexor) in patients (pts) with heavily pretreated non-Hodgkin lymphoma (NHL)
Holgersson et al. A phase I pilot study of the insulin-like growth factor 1 receptor pathway modulator AXL1717 in combination with gemcitabine HCl and carboplatin in previously untreated, locally advanced, or metastatic non-small cell lung cancer
Maruyama et al. Therapeutic strategy for the treatment of postoperative recurrence of esophageal squamous cell carcinoma: clinical efficacy of radiotherapy
JP6656484B2 (ja) 放射性抗腫瘍剤
Willett et al. Radiation therapy in stage II and III rectal cancer
Jeremić et al. Concurrent hyperfractionated radiation therapy and chemotherapy in locally advanced (Stage III) non-small-cell lung cancer: single institution experience with 600 patients

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170403

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170403

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170829

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170904

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180202

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180521